<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230821140833&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230821140833&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Mon, 21 Aug 2023 18:08:35 +0000</lastbuilddate>
<pubDate>Mon, 21 Aug 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Improved Cardiac Function in Postischemic Rats Using an Optimized Cardiac Reprogramming Cocktail Delivered in a Single Novel Adeno-Associated Virus</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37602409/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230821140833&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Collectively, these results advance the application of cardiac reprogramming gene therapy as a viable therapeutic approach to treat chronic heart failure resulting from ischemic injury.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 21. doi: 10.1161/CIRCULATIONAHA.122.061542. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiac reprogramming is a technique to directly convert nonmyocytes into myocardial cells using genes or small molecules. This intervention provides functional benefit to the rodent heart when delivered at the time of myocardial infarction or activated transgenically up to 4 weeks after myocardial infarction. Yet, several hurdles have prevented the advancement of cardiac reprogramming for clinical use.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Through a combination of screening and rational design, we identified a cardiac reprogramming cocktail that can be encoded in a single adeno-associated virus. We also created a novel adeno-associated virus capsid that can transduce cardiac fibroblasts more efficiently than available parental serotypes by mutating posttranslationally modified capsid residues. Because a constitutive promoter was needed to drive high expression of these cell fate-altering reprogramming factors, we included binding sites to a cardiomyocyte-restricted microRNA within the 3' untranslated region of the expression cassette that limits expression to nonmyocytes. After optimizing this expression cassette to reprogram human cardiac fibroblasts into induced cardiomyocyte-like cells in vitro, we also tested the ability of this capsid/cassette combination to confer functional benefit in acute mouse myocardial infarction and chronic rat myocardial infarction models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We demonstrated sustained, dose-dependent improvement in cardiac function when treating a rat model 2 weeks after myocardial infarction, showing that cardiac reprogramming, when delivered in a single, clinically relevant adeno-associated virus vector, can support functional improvement in the postremodeled heart. This benefit was not observed with GFP (green fluorescent protein) or a hepatocyte reprogramming cocktail and was achieved even in the presence of immunosuppression, supporting myocyte formation as the underlying mechanism.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Collectively, these results advance the application of cardiac reprogramming gene therapy as a viable therapeutic approach to treat chronic heart failure resulting from ischemic injury.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37602409/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230821140833&v=2.17.9.post6+86293ac">37602409</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.061542>10.1161/CIRCULATIONAHA.122.061542</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37602409</guid>
<pubDate>Mon, 21 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Huanyu Zhou</dc:creator>
<dc:creator>Jin Yang</dc:creator>
<dc:creator>Chetan Srinath</dc:creator>
<dc:creator>Aliya Zeng</dc:creator>
<dc:creator>Iris Wu</dc:creator>
<dc:creator>Elena C Leon</dc:creator>
<dc:creator>Tawny Neal Qureshi</dc:creator>
<dc:creator>Christopher A Reid</dc:creator>
<dc:creator>Emily R Nettesheim</dc:creator>
<dc:creator>Emma Xu</dc:creator>
<dc:creator>Zoe Duclos</dc:creator>
<dc:creator>Tamer M A Mohamed</dc:creator>
<dc:creator>Farshad Farshidfar</dc:creator>
<dc:creator>Anthony Fejes</dc:creator>
<dc:creator>Jun Liu</dc:creator>
<dc:creator>Samantha Jones</dc:creator>
<dc:creator>Charles Feathers</dc:creator>
<dc:creator>Tae Won Chung</dc:creator>
<dc:creator>Frank Jing</dc:creator>
<dc:creator>William S Prince</dc:creator>
<dc:creator>JianMin Lin</dc:creator>
<dc:creator>Pengzhi Yu</dc:creator>
<dc:creator>Deepak Srivastava</dc:creator>
<dc:creator>Timothy Hoey</dc:creator>
<dc:creator>Kathryn N Ivey</dc:creator>
<dc:creator>Laura M Lombardi</dc:creator>
<dc:date>2023-08-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Improved Cardiac Function in Postischemic Rats Using an Optimized Cardiac Reprogramming Cocktail Delivered in a Single Novel Adeno-Associated Virus</dc:title>
<dc:identifier>pmid:37602409</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.061542</dc:identifier>
</item>
<item>
<title>Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37602376/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230821140833&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: At 3-year follow-up, there was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI with current-generation drug-eluting stents compared with CABG. There was a higher incidence of MI after PCI compared with CABG, with no difference in death or stroke. These results provide contemporary data to allow improved shared decision-making between physicians and patients with 3-vessel coronary artery disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 21. doi: 10.1161/CIRCULATIONAHA.123.065770. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Previous studies comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG) in patients with multivessel coronary disease not involving the left main have shown significantly lower rates of death, myocardial infarction (MI), or stroke after CABG. These studies did not routinely use current-generation drug-eluting stents or fractional flow reserve (FFR) to guide PCI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: FAME 3 (Fractional Flow Reserve versus Angiography for Multivessel Evaluation) is an investigator-initiated, multicenter, international, randomized trial involving patients with 3-vessel coronary artery disease (not involving the left main coronary artery) in 48 centers worldwide. Patients were randomly assigned to receive FFR-guided PCI using zotarolimus drug-eluting stents or CABG. The prespecified key secondary end point of the trial reported here is the 3-year incidence of the composite of death, MI, or stroke.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 1500 patients were randomized to FFR-guided PCI or CABG. Follow-up was achieved in >;96% of patients in both groups. There was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI compared with CABG (12.0% versus 9.2%; hazard ratio [HR], 1.3 [95% CI, 0.98-1.83]; <i>P</i>=0.07). The rates of death (4.1% versus 3.9%; HR, 1.0 [95% CI, 0.6-1.7]; <i>P</i>=0.88) and stroke (1.6% versus 2.0%; HR, 0.8 [95% CI, 0.4-1.7]; <i>P</i>=0.56) were not different. MI occurred more frequently after PCI (7.0% versus 4.2%; HR, 1.7 [95% CI, 1.1-2.7]; <i>P</i>=0.02).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: At 3-year follow-up, there was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI with current-generation drug-eluting stents compared with CABG. There was a higher incidence of MI after PCI compared with CABG, with no difference in death or stroke. These results provide contemporary data to allow improved shared decision-making between physicians and patients with 3-vessel coronary artery disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICALTRIALS: gov; Unique identifier: NCT02100722.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37602376/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230821140833&v=2.17.9.post6+86293ac">37602376</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065770>10.1161/CIRCULATIONAHA.123.065770</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37602376</guid>
<pubDate>Mon, 21 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Frederik M Zimmermann</dc:creator>
<dc:creator>Victoria Y Ding</dc:creator>
<dc:creator>Nico H J Pijls</dc:creator>
<dc:creator>Zsolt Piroth</dc:creator>
<dc:creator>Albert H M van Straten</dc:creator>
<dc:creator>Laszlo Szekely</dc:creator>
<dc:creator>Giedrius Davidavicius</dc:creator>
<dc:creator>Gintaras Kalinauskas</dc:creator>
<dc:creator>Samer Mansour</dc:creator>
<dc:creator>Rajesh Kharbanda</dc:creator>
<dc:creator>Nikolaos Östlund-Papadogeorgos</dc:creator>
<dc:creator>Adel Aminian</dc:creator>
<dc:creator>Keith G Oldroyd</dc:creator>
<dc:creator>Nawwar Al-Attar</dc:creator>
<dc:creator>Nikola Jagic</dc:creator>
<dc:creator>Jan-Henk E Dambrink</dc:creator>
<dc:creator>Petr Kala</dc:creator>
<dc:creator>Oskar Angeras</dc:creator>
<dc:creator>Philip MacCarthy</dc:creator>
<dc:creator>Olaf Wendler</dc:creator>
<dc:creator>Filip Casselman</dc:creator>
<dc:creator>Nils Witt</dc:creator>
<dc:creator>Kreton Mavromatis</dc:creator>
<dc:creator>Steven E S Miner</dc:creator>
<dc:creator>Jaydeep Sarma</dc:creator>
<dc:creator>Thomas Engstrøm</dc:creator>
<dc:creator>Evald H Christiansen</dc:creator>
<dc:creator>Pim A L Tonino</dc:creator>
<dc:creator>Michael J Reardon</dc:creator>
<dc:creator>Hisao Otsuki</dc:creator>
<dc:creator>Yuhei Kobayashi</dc:creator>
<dc:creator>Mark A Hlatky</dc:creator>
<dc:creator>Kenneth W Mahaffey</dc:creator>
<dc:creator>Manisha Desai</dc:creator>
<dc:creator>Y Joseph Woo</dc:creator>
<dc:creator>Alan C Yeung</dc:creator>
<dc:creator>Bernard De Bruyne</dc:creator>
<dc:creator>William F Fearon</dc:creator>
<dc:creator>FAME 3 Investigators</dc:creator>
<dc:date>2023-08-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial</dc:title>
<dc:identifier>pmid:37602376</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065770</dc:identifier>
</item>
<item>
<title>Epilepsy and long-term risk of arrhythmias</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37602368/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230821140833&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSION: This study revealed the higher risk of cardiac arrhythmias persists long term in people with epilepsy, especially among those using carbamazepine and valproic acid. These findings highlight the need for regular heart rhythm monitoring and management in people with epilepsy in order to reduce the risk of further cardiovascular complications.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 21:ehad523. doi: 10.1093/eurheartj/ehad523. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Previous evidence has mainly supported transient changes in cardiac function during interictal or peri-ictal phases in people with epilepsy, but the long-term risk of cardiac arrhythmias is poorly described. This study aimed to assess the long-term association of epilepsy with cardiac arrhythmias, considering the potential role of genetic predisposition and antiseizure medications (ASMs) in any associations observed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This population-based study evaluated UK Biobank data for individuals recruited between 2006 and 2010. Cox proportional hazards models and competing risk models were used to examine the association of epilepsy history with the long-term incidence risk of cardiac arrhythmias and arrhythmias subtypes. Polygenic risk scores (PRS) were calculated to investigate the effect of genetic susceptibility. The role of ASMs was also evaluated by integrating observational and drug target Mendelian randomization (MR) evidence.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study included 329 432 individuals, including 2699 people with epilepsy. Compared with those without epilepsy, people with epilepsy experienced an increased risk of all cardiac arrhythmias [hazard ratio (HR) 1.36, 95% confidence interval (CI) 1.21-1.53], atrial fibrillation (HR 1.26, 95% CI 1.08-1.46), and other cardiac arrhythmias (HR 1.56, 95% CI 1.34-1.81). The associations were not modified by genetic predisposition as indicated by PRS. Competing and sensitivity analyses corroborated these results. Individuals with epilepsy using ASMs, especially carbamazepine and valproic acid, were at a higher risk for cardiac arrhythmias. This observation was further supported by drug target MR results (PSMR &lt; .05 and PHEIDI >; .05).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: This study revealed the higher risk of cardiac arrhythmias persists long term in people with epilepsy, especially among those using carbamazepine and valproic acid. These findings highlight the need for regular heart rhythm monitoring and management in people with epilepsy in order to reduce the risk of further cardiovascular complications.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37602368/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230821140833&v=2.17.9.post6+86293ac">37602368</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad523>10.1093/eurheartj/ehad523</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37602368</guid>
<pubDate>Mon, 21 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Jie Wang</dc:creator>
<dc:creator>Peiyuan Huang</dc:creator>
<dc:creator>Qingwei Yu</dc:creator>
<dc:creator>Jun Lu</dc:creator>
<dc:creator>Pinbo Liu</dc:creator>
<dc:creator>Yiping Yang</dc:creator>
<dc:creator>Zeying Feng</dc:creator>
<dc:creator>Jingjing Cai</dc:creator>
<dc:creator>Guoping Yang</dc:creator>
<dc:creator>Hong Yuan</dc:creator>
<dc:creator>Haibo Tang</dc:creator>
<dc:creator>Yao Lu</dc:creator>
<dc:date>2023-08-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Epilepsy and long-term risk of arrhythmias</dc:title>
<dc:identifier>pmid:37602368</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad523</dc:identifier>
</item>
<item>
<title>Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37599464/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230821140833&amp;v=2.17.9.post6+86293ac
      <description>Obesity is a modifiable cardiovascular risk factor, but adipose tissue (AT) depots in humans are anatomically, histologically, and functionally heterogeneous. For example, visceral AT is a pro-atherogenic secretory AT depot, while subcutaneous AT represents a more classical energy storage depot. Perivascular adipose tissue (PVAT) regulates vascular biology via paracrine cross-talk signals. In this position paper, the state-of-the-art knowledge of various AT depots is reviewed providing a...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 21:ehad484. doi: 10.1093/eurheartj/ehad484. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Obesity is a modifiable cardiovascular risk factor, but adipose tissue (AT) depots in humans are anatomically, histologically, and functionally heterogeneous. For example, visceral AT is a pro-atherogenic secretory AT depot, while subcutaneous AT represents a more classical energy storage depot. Perivascular adipose tissue (PVAT) regulates vascular biology via paracrine cross-talk signals. In this position paper, the state-of-the-art knowledge of various AT depots is reviewed providing a consensus definition of PVAT around the coronary arteries, as the AT surrounding the artery up to a distance from its outer wall equal to the luminal diameter of the artery. Special focus is given to the interactions between PVAT and the vascular wall that render PVAT a potential therapeutic target in cardiovascular diseases. This Clinical Consensus Statement also discusses the role of PVAT as a clinically relevant source of diagnostic and prognostic biomarkers of vascular function, which may guide precision medicine in atherosclerosis, hypertension, heart failure, and other cardiovascular diseases. In this article, its role as a 'biosensor' of vascular inflammation is highlighted with description of recent imaging technologies that visualize PVAT in clinical practice, allowing non-invasive quantification of coronary inflammation and the related residual cardiovascular inflammatory risk, guiding deployment of therapeutic interventions. Finally, the current and future clinical applicability of artificial intelligence and machine learning technologies is reviewed that integrate PVAT information into prognostic models to provide clinically meaningful information in primary and secondary prevention.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37599464/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230821140833&v=2.17.9.post6+86293ac">37599464</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad484>10.1093/eurheartj/ehad484</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37599464</guid>
<pubDate>Mon, 21 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Charalambos Antoniades</dc:creator>
<dc:creator>Dimitris Tousoulis</dc:creator>
<dc:creator>Marija Vavlukis</dc:creator>
<dc:creator>Ingrid Fleming</dc:creator>
<dc:creator>Dirk J Duncker</dc:creator>
<dc:creator>Etto Eringa</dc:creator>
<dc:creator>Olivia Manfrini</dc:creator>
<dc:creator>Alexios S Antonopoulos</dc:creator>
<dc:creator>Evangelos Oikonomou</dc:creator>
<dc:creator>Teresa Padró</dc:creator>
<dc:creator>Danijela Trifunovic-Zamaklar</dc:creator>
<dc:creator>Giuseppe De Luca</dc:creator>
<dc:creator>Tomasz Guzik</dc:creator>
<dc:creator>Edina Cenko</dc:creator>
<dc:creator>Ana Djordjevic-Dikic</dc:creator>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2023-08-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers</dc:title>
<dc:identifier>pmid:37599464</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad484</dc:identifier>
</item>
<item>
<title>Epigenetic memory of coronavirus infection in innate immune cells and their progenitors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37597510/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230821140833&amp;v=2.17.9.post6+86293ac
      <description>Inflammation can trigger lasting phenotypes in immune and non-immune cells. Whether and how human infections and associated inflammation can form innate immune memory in hematopoietic stem and progenitor cells (HSPC) has remained unclear. We found that circulating HSPC, enriched from peripheral blood, captured the diversity of bone marrow HSPC, enabling investigation of their epigenomic reprogramming following coronavirus disease 2019 (COVID-19). Alterations in innate immune phenotypes and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 15:S0092-8674(23)00796-1. doi: 10.1016/j.cell.2023.07.019. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Inflammation can trigger lasting phenotypes in immune and non-immune cells. Whether and how human infections and associated inflammation can form innate immune memory in hematopoietic stem and progenitor cells (HSPC) has remained unclear. We found that circulating HSPC, enriched from peripheral blood, captured the diversity of bone marrow HSPC, enabling investigation of their epigenomic reprogramming following coronavirus disease 2019 (COVID-19). Alterations in innate immune phenotypes and epigenetic programs of HSPC persisted for months to 1 year following severe COVID-19 and were associated with distinct transcription factor (TF) activities, altered regulation of inflammatory programs, and durable increases in myelopoiesis. HSPC epigenomic alterations were conveyed, through differentiation, to progeny innate immune cells. Early activity of IL-6 contributed to these persistent phenotypes in human COVID-19 and a mouse coronavirus infection model. Epigenetic reprogramming of HSPC may underlie altered immune function following infection and be broadly relevant, especially for millions of COVID-19 survivors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37597510/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230821140833&v=2.17.9.post6+86293ac">37597510</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.07.019>10.1016/j.cell.2023.07.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37597510</guid>
<pubDate>Sat, 19 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Jin-Gyu Cheong</dc:creator>
<dc:creator>Arjun Ravishankar</dc:creator>
<dc:creator>Siddhartha Sharma</dc:creator>
<dc:creator>Christopher N Parkhurst</dc:creator>
<dc:creator>Simon A Grassmann</dc:creator>
<dc:creator>Claire K Wingert</dc:creator>
<dc:creator>Paoline Laurent</dc:creator>
<dc:creator>Sai Ma</dc:creator>
<dc:creator>Lucinda Paddock</dc:creator>
<dc:creator>Isabella C Miranda</dc:creator>
<dc:creator>Emin Onur Karakaslar</dc:creator>
<dc:creator>Djamel Nehar-Belaid</dc:creator>
<dc:creator>Asa Thibodeau</dc:creator>
<dc:creator>Michael J Bale</dc:creator>
<dc:creator>Vinay K Kartha</dc:creator>
<dc:creator>Jim K Yee</dc:creator>
<dc:creator>Minh Y Mays</dc:creator>
<dc:creator>Chenyang Jiang</dc:creator>
<dc:creator>Andrew W Daman</dc:creator>
<dc:creator>Alexia Martinez de Paz</dc:creator>
<dc:creator>Dughan Ahimovic</dc:creator>
<dc:creator>Victor Ramos</dc:creator>
<dc:creator>Alexander Lercher</dc:creator>
<dc:creator>Erik Nielsen</dc:creator>
<dc:creator>Sergio Alvarez-Mulett</dc:creator>
<dc:creator>Ling Zheng</dc:creator>
<dc:creator>Andrew Earl</dc:creator>
<dc:creator>Alisha Yallowitz</dc:creator>
<dc:creator>Lexi Robbins</dc:creator>
<dc:creator>Elyse LaFond</dc:creator>
<dc:creator>Karissa L Weidman</dc:creator>
<dc:creator>Sabrina Racine-Brzostek</dc:creator>
<dc:creator>He S Yang</dc:creator>
<dc:creator>David R Price</dc:creator>
<dc:creator>Louise Leyre</dc:creator>
<dc:creator>André F Rendeiro</dc:creator>
<dc:creator>Hiranmayi Ravichandran</dc:creator>
<dc:creator>Junbum Kim</dc:creator>
<dc:creator>Alain C Borczuk</dc:creator>
<dc:creator>Charles M Rice</dc:creator>
<dc:creator>R Brad Jones</dc:creator>
<dc:creator>Edward J Schenck</dc:creator>
<dc:creator>Robert J Kaner</dc:creator>
<dc:creator>Amy Chadburn</dc:creator>
<dc:creator>Zhen Zhao</dc:creator>
<dc:creator>Virginia Pascual</dc:creator>
<dc:creator>Olivier Elemento</dc:creator>
<dc:creator>Robert E Schwartz</dc:creator>
<dc:creator>Jason D Buenrostro</dc:creator>
<dc:creator>Rachel E Niec</dc:creator>
<dc:creator>Franck J Barrat</dc:creator>
<dc:creator>Lindsay Lief</dc:creator>
<dc:creator>Joseph C Sun</dc:creator>
<dc:creator>Duygu Ucar</dc:creator>
<dc:creator>Steven Z Josefowicz</dc:creator>
<dc:date>2023-08-19</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Epigenetic memory of coronavirus infection in innate immune cells and their progenitors</dc:title>
<dc:identifier>pmid:37597510</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.07.019</dc:identifier>
</item>
<item>
<title>Plaque morphology, inflammation, and outcome: cautious and tempered interpretation warranted</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37596979/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230821140833&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 19:ehad527. doi: 10.1093/eurheartj/ehad527. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37596979/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230821140833&v=2.17.9.post6+86293ac">37596979</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad527>10.1093/eurheartj/ehad527</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37596979</guid>
<pubDate>Sat, 19 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Steven E Nissen</dc:creator>
<dc:date>2023-08-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Plaque morphology, inflammation, and outcome: cautious and tempered interpretation warranted</dc:title>
<dc:identifier>pmid:37596979</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad527</dc:identifier>
</item>
<item>
<title>Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37595566/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230821140833&amp;v=2.17.9.post6+86293ac
      <description>Mucosal-associated invariant T (MAIT) cells represent an abundant innate-like T cell subtype in the human liver. MAIT cells are assigned crucial roles in regulating immunity and inflammation, yet their role in liver cancer remains elusive. Here, we present a MAIT cell-centered profiling of hepatocellular carcinoma (HCC) using scRNA-seq, flow cytometry, and co-detection by indexing (CODEX) imaging of paired patient samples. These analyses highlight the heterogeneity and dysfunctionality of MAIT...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 17;186(17):3686-3705.e32. doi: 10.1016/j.cell.2023.07.026.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Mucosal-associated invariant T (MAIT) cells represent an abundant innate-like T cell subtype in the human liver. MAIT cells are assigned crucial roles in regulating immunity and inflammation, yet their role in liver cancer remains elusive. Here, we present a MAIT cell-centered profiling of hepatocellular carcinoma (HCC) using scRNA-seq, flow cytometry, and co-detection by indexing (CODEX) imaging of paired patient samples. These analyses highlight the heterogeneity and dysfunctionality of MAIT cells in HCC and their defective capacity to infiltrate liver tumors. Machine-learning tools were used to dissect the spatial cellular interaction network within the MAIT cell neighborhood. Co-localization in the adjacent liver and interaction between niche-occupying CSF1R<sup>+</sup>PD-L1<sup>+</sup> tumor-associated macrophages (TAMs) and MAIT cells was identified as a key regulatory element of MAIT cell dysfunction. Perturbation of this cell-cell interaction in ex vivo co-culture studies using patient samples and murine models reinvigorated MAIT cell cytotoxicity. These studies suggest that aPD-1/aPD-L1 therapies target MAIT cells in HCC patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37595566/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230821140833&v=2.17.9.post6+86293ac">37595566</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.07.026>10.1016/j.cell.2023.07.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37595566</guid>
<pubDate>Fri, 18 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Benjamin Ruf</dc:creator>
<dc:creator>Matthias Bruhns</dc:creator>
<dc:creator>Sepideh Babaei</dc:creator>
<dc:creator>Noemi Kedei</dc:creator>
<dc:creator>Lichun Ma</dc:creator>
<dc:creator>Mahler Revsine</dc:creator>
<dc:creator>Mohamed-Reda Benmebarek</dc:creator>
<dc:creator>Chi Ma</dc:creator>
<dc:creator>Bernd Heinrich</dc:creator>
<dc:creator>Varun Subramanyam</dc:creator>
<dc:creator>Jonathan Qi</dc:creator>
<dc:creator>Simon Wabitsch</dc:creator>
<dc:creator>Benjamin L Green</dc:creator>
<dc:creator>Kylynda C Bauer</dc:creator>
<dc:creator>Yuta Myojin</dc:creator>
<dc:creator>Layla T Greten</dc:creator>
<dc:creator>Justin D McCallen</dc:creator>
<dc:creator>Patrick Huang</dc:creator>
<dc:creator>Rajiv Trehan</dc:creator>
<dc:creator>Xin Wang</dc:creator>
<dc:creator>Amran Nur</dc:creator>
<dc:creator>Dana Qiang Murphy Soika</dc:creator>
<dc:creator>Marie Pouzolles</dc:creator>
<dc:creator>Christine N Evans</dc:creator>
<dc:creator>Raj Chari</dc:creator>
<dc:creator>David E Kleiner</dc:creator>
<dc:creator>William Telford</dc:creator>
<dc:creator>Kimia Dadkhah</dc:creator>
<dc:creator>Allison Ruchinskas</dc:creator>
<dc:creator>Merrill K Stovroff</dc:creator>
<dc:creator>Jiman Kang</dc:creator>
<dc:creator>Kesha Oza</dc:creator>
<dc:creator>Mathuros Ruchirawat</dc:creator>
<dc:creator>Alexander Kroemer</dc:creator>
<dc:creator>Xin Wei Wang</dc:creator>
<dc:creator>Manfred Claassen</dc:creator>
<dc:creator>Firouzeh Korangy</dc:creator>
<dc:creator>Tim F Greten</dc:creator>
<dc:date>2023-08-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin</dc:title>
<dc:identifier>pmid:37595566</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.07.026</dc:identifier>
</item>
<item>
<title>A conserved family of immune effectors cleaves cellular ATP upon viral infection</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37595565/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230821140833&amp;v=2.17.9.post6+86293ac
      <description>During viral infection, cells can deploy immune strategies that deprive viruses of molecules essential for their replication. Here, we report a family of immune effectors in bacteria that, upon phage infection, degrade cellular adenosine triphosphate (ATP) and deoxyadenosine triphosphate (dATP) by cleaving the N-glycosidic bond between the adenine and sugar moieties. These ATP nucleosidase effectors are widely distributed within multiple bacterial defense systems, including cyclic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 17;186(17):3619-3631.e13. doi: 10.1016/j.cell.2023.07.020.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">During viral infection, cells can deploy immune strategies that deprive viruses of molecules essential for their replication. Here, we report a family of immune effectors in bacteria that, upon phage infection, degrade cellular adenosine triphosphate (ATP) and deoxyadenosine triphosphate (dATP) by cleaving the N-glycosidic bond between the adenine and sugar moieties. These ATP nucleosidase effectors are widely distributed within multiple bacterial defense systems, including cyclic oligonucleotide-based antiviral signaling systems (CBASS), prokaryotic argonautes, and nucleotide-binding leucine-rich repeat (NLR)-like proteins, and we show that ATP and dATP degradation during infection halts phage propagation. By analyzing homologs of the immune ATP nucleosidase domain, we discover and characterize Detocs, a family of bacterial defense systems with a two-component phosphotransfer-signaling architecture. The immune ATP nucleosidase domain is also encoded within diverse eukaryotic proteins with immune-like architectures, and we show biochemically that eukaryotic homologs preserve the ATP nucleosidase activity. Our findings suggest that ATP and dATP degradation is a cell-autonomous innate immune strategy conserved across the tree of life.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37595565/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230821140833&v=2.17.9.post6+86293ac">37595565</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.07.020>10.1016/j.cell.2023.07.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37595565</guid>
<pubDate>Fri, 18 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Francois Rousset</dc:creator>
<dc:creator>Erez Yirmiya</dc:creator>
<dc:creator>Shahar Nesher</dc:creator>
<dc:creator>Alexander Brandis</dc:creator>
<dc:creator>Tevie Mehlman</dc:creator>
<dc:creator>Maxim Itkin</dc:creator>
<dc:creator>Sergey Malitsky</dc:creator>
<dc:creator>Adi Millman</dc:creator>
<dc:creator>Sarah Melamed</dc:creator>
<dc:creator>Rotem Sorek</dc:creator>
<dc:date>2023-08-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A conserved family of immune effectors cleaves cellular ATP upon viral infection</dc:title>
<dc:identifier>pmid:37595565</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.07.020</dc:identifier>
</item>
<item>
<title>An ethical framework for human embryology with embryo models</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37595564/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230821140833&amp;v=2.17.9.post6+86293ac
      <description>A human embryo's legal definition and its entitlement to protection vary greatly worldwide. Recently, human pluripotent stem cells have been used to form in vitro models of early embryos that have challenged legal definitions and raised questions regarding their usage. In this light, we propose a refined legal definition of an embryo, suggest "tipping points" for when human embryo models could eventually be afforded similar protection to that of embryos, and then revisit basic ethical principles...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 17;186(17):3548-3557. doi: 10.1016/j.cell.2023.07.028.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">A human embryo's legal definition and its entitlement to protection vary greatly worldwide. Recently, human pluripotent stem cells have been used to form in vitro models of early embryos that have challenged legal definitions and raised questions regarding their usage. In this light, we propose a refined legal definition of an embryo, suggest "tipping points" for when human embryo models could eventually be afforded similar protection to that of embryos, and then revisit basic ethical principles that might help to draft a roadmap for the gradual, justified usage of embryo models in a manner that aims to maximize benefits to society.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37595564/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230821140833&v=2.17.9.post6+86293ac">37595564</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.07.028>10.1016/j.cell.2023.07.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37595564</guid>
<pubDate>Fri, 18 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Nicolas C Rivron</dc:creator>
<dc:creator>Alfonso Martinez Arias</dc:creator>
<dc:creator>Martin F Pera</dc:creator>
<dc:creator>Naomi Moris</dc:creator>
<dc:creator>Hafez Ismaili M'hamdi</dc:creator>
<dc:date>2023-08-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>An ethical framework for human embryology with embryo models</dc:title>
<dc:identifier>pmid:37595564</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.07.028</dc:identifier>
</item>
<item>
<title>Insights and strategies for improving equity in graduate school admissions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37595563/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230821140833&amp;v=2.17.9.post6+86293ac
      <description>Applying to graduate school can be particularly challenging for students from historically minoritized backgrounds due to a hidden curriculum in the graduate admissions process. To address this issue, a team of volunteer STEM trainees established the Científico Latino Graduate Student Mentorship Initiative (CL-GSMI) in 2019 to support applicants from historically minoritized backgrounds. CL-GSMI is designed to improve access to critical resources, including information, mentorship, and financial...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 17;186(17):3529-3547. doi: 10.1016/j.cell.2023.07.029.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Applying to graduate school can be particularly challenging for students from historically minoritized backgrounds due to a hidden curriculum in the graduate admissions process. To address this issue, a team of volunteer STEM trainees established the Científico Latino Graduate Student Mentorship Initiative (CL-GSMI) in 2019 to support applicants from historically minoritized backgrounds. CL-GSMI is designed to improve access to critical resources, including information, mentorship, and financial support, and has assisted 443 students in applying and matriculating to graduate school. Using program evaluation data from 2020 to 2021, we highlight areas in graduate school admissions that can be improved to promote equity and inclusion.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37595563/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230821140833&v=2.17.9.post6+86293ac">37595563</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.07.029>10.1016/j.cell.2023.07.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37595563</guid>
<pubDate>Fri, 18 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Melissa Andrea Cadena</dc:creator>
<dc:creator>Cathy Amaya</dc:creator>
<dc:creator>Daisy Duan</dc:creator>
<dc:creator>Carlos Alberto Rico</dc:creator>
<dc:creator>Leonor García-Bayona</dc:creator>
<dc:creator>Aníbal Tornes Blanco</dc:creator>
<dc:creator>Yessica Santana Agreda</dc:creator>
<dc:creator>Gonzalo Javier Villegas Rodríguez</dc:creator>
<dc:creator>Alexis Ceja</dc:creator>
<dc:creator>Vianna G Martinez</dc:creator>
<dc:creator>Olivia V Goldman</dc:creator>
<dc:creator>Robert W Fernandez</dc:creator>
<dc:date>2023-08-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Insights and strategies for improving equity in graduate school admissions</dc:title>
<dc:identifier>pmid:37595563</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.07.029</dc:identifier>
</item>
<item>
<title>RNA "COURIERs": Enabling synthetic cell-to-cell communication in human cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37595562/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230821140833&amp;v=2.17.9.post6+86293ac
      <description>The development of molecular couriers to selectively package, export, and recover RNA molecules within human cells is a significant challenge. In this issue of Cell, Horns et al.¹ introduce cellular RNA exporters, termed COURIERs, that package, secrete, and protect RNA cargo and establish the foundation for sophisticated cell-to-cell RNA communication.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 17;186(17):3526-3528. doi: 10.1016/j.cell.2023.07.030.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The development of molecular couriers to selectively package, export, and recover RNA molecules within human cells is a significant challenge. In this issue of Cell, Horns et al.<sup>1</sup> introduce cellular RNA exporters, termed COURIERs, that package, secrete, and protect RNA cargo and establish the foundation for sophisticated cell-to-cell RNA communication.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37595562/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230821140833&v=2.17.9.post6+86293ac">37595562</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.07.030>10.1016/j.cell.2023.07.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37595562</guid>
<pubDate>Fri, 18 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Taek Kang</dc:creator>
<dc:creator>Leonidas Bleris</dc:creator>
<dc:date>2023-08-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>RNA "COURIERs": Enabling synthetic cell-to-cell communication in human cells</dc:title>
<dc:identifier>pmid:37595562</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.07.030</dc:identifier>
</item>
<item>
<title>The calvaria stands alone: Unique aspects of the skull bone marrow-meninges border</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37595561/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230821140833&amp;v=2.17.9.post6+86293ac
      <description>Channels connecting the skull bone marrow and the meninges have recently been discovered as a path for immune cell and molecule trafficking. In this issue of Cell, Kolabas, Kuemmerle, Perneczky, Förstera, and colleagues characterize these channels in humans and mice, revealing unique features of skull bone marrow and localized activation in human pathology.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 17;186(17):3524-3526. doi: 10.1016/j.cell.2023.07.025.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Channels connecting the skull bone marrow and the meninges have recently been discovered as a path for immune cell and molecule trafficking. In this issue of Cell, Kolabas, Kuemmerle, Perneczky, Förstera, and colleagues characterize these channels in humans and mice, revealing unique features of skull bone marrow and localized activation in human pathology.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37595561/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230821140833&v=2.17.9.post6+86293ac">37595561</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.07.025>10.1016/j.cell.2023.07.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37595561</guid>
<pubDate>Fri, 18 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Sachin P Gadani</dc:creator>
<dc:creator>Peter A Calabresi</dc:creator>
<dc:date>2023-08-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The calvaria stands alone: Unique aspects of the skull bone marrow-meninges border</dc:title>
<dc:identifier>pmid:37595561</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.07.025</dc:identifier>
</item>
<item>
<title>Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37595560/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230821140833&amp;v=2.17.9.post6+86293ac
      <description>The FDA has recently approved Krystal biotech's beremagene geperpavec (B-VEC, Vyjuvek) to treat the wounds of dystrophic epidermolysis bullosa (DEB) patients. This represents a giant step, not only toward the treatment of this devastating disease, but also for the whole field of non-replicative (nr) recombinant HSV-1 vectors for gene therapy. To view this Bench to Bedside, open or download the PDF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 17;186(17):3523-3523.e1. doi: 10.1016/j.cell.2023.07.031.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The FDA has recently approved Krystal biotech's beremagene geperpavec (B-VEC, Vyjuvek) to treat the wounds of dystrophic epidermolysis bullosa (DEB) patients. This represents a giant step, not only toward the treatment of this devastating disease, but also for the whole field of non-replicative (nr) recombinant HSV-1 vectors for gene therapy. To view this Bench to Bedside, open or download the PDF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37595560/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230821140833&v=2.17.9.post6+86293ac">37595560</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.07.031>10.1016/j.cell.2023.07.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37595560</guid>
<pubDate>Fri, 18 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Alberto L Epstein</dc:creator>
<dc:creator>Cornelia Haag-Molkenteller</dc:creator>
<dc:date>2023-08-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB)</dc:title>
<dc:identifier>pmid:37595560</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.07.031</dc:identifier>
</item>
<item>
<title>JAMA Network Call for Papers on Health and the 2024 US Election</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37594888/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230821140833&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 18. doi: 10.1001/jamacardio.2023.2857. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37594888/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230821140833&v=2.17.9.post6+86293ac">37594888</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2857>10.1001/jamacardio.2023.2857</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37594888</guid>
<pubDate>Fri, 18 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Alison Galbraith</dc:creator>
<dc:creator>Annette Flanagin</dc:creator>
<dc:creator>Aaron E Carroll</dc:creator>
<dc:creator>John Z Ayanian</dc:creator>
<dc:creator>Robert O Bonow</dc:creator>
<dc:creator>Neil Bressler</dc:creator>
<dc:creator>Dimitri Christakis</dc:creator>
<dc:creator>Mary L Nora Disis</dc:creator>
<dc:creator>Sharon K Inouye</dc:creator>
<dc:creator>Andrew Josephson</dc:creator>
<dc:creator>Dost Öngür</dc:creator>
<dc:creator>Jay F Piccirillo</dc:creator>
<dc:creator>Kanade Shinkai</dc:creator>
<dc:creator>Kirsten Bibbins-Domingo</dc:creator>
<dc:date>2023-08-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Network Call for Papers on Health and the 2024 US Election</dc:title>
<dc:identifier>pmid:37594888</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2857</dc:identifier>
</item>
<item>
<title>Optical Control of Cardiac Rhythm by In Vivo Photoactivation of an ERG Channel Peptide Inhibitor</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37593901/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230821140833&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Aug 18. doi: 10.1161/CIRCRESAHA.123.322880. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37593901/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230821140833&v=2.17.9.post6+86293ac">37593901</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322880>10.1161/CIRCRESAHA.123.322880</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37593901</guid>
<pubDate>Fri, 18 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Jérôme Montnach</dc:creator>
<dc:creator>Hugo Millet</dc:creator>
<dc:creator>Antoine Persello</dc:creator>
<dc:creator>Hervé Meudal</dc:creator>
<dc:creator>Stephan De Waard</dc:creator>
<dc:creator>Pietro Mesrica</dc:creator>
<dc:creator>Barbara Ribeiro</dc:creator>
<dc:creator>Jérémie Richard</dc:creator>
<dc:creator>Agnès Hivonnait</dc:creator>
<dc:creator>Agnès Tessier</dc:creator>
<dc:creator>Benjamin Lauzier</dc:creator>
<dc:creator>Flavien Charpentier</dc:creator>
<dc:creator>Matteo E Mangoni</dc:creator>
<dc:creator>Céline Landon</dc:creator>
<dc:creator>Chris Jopling</dc:creator>
<dc:creator>Michel De Waard</dc:creator>
<dc:date>2023-08-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Optical Control of Cardiac Rhythm by In Vivo Photoactivation of an ERG Channel Peptide Inhibitor</dc:title>
<dc:identifier>pmid:37593901</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322880</dc:identifier>
</item>
<item>
<title>Physical activity patterns and cardiovascular health: 'yes, weekend!'</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37592862/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230821140833&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 18:ehad520. doi: 10.1093/eurheartj/ehad520. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37592862/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230821140833&v=2.17.9.post6+86293ac">37592862</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad520>10.1093/eurheartj/ehad520</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37592862</guid>
<pubDate>Fri, 18 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Leonarda Galiuto</dc:creator>
<dc:date>2023-08-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Physical activity patterns and cardiovascular health: 'yes, weekend!'</dc:title>
<dc:identifier>pmid:37592862</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad520</dc:identifier>
</item>
<item>
<title>Ready for rapid rule-out of acute myocardial infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37592857/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230821140833&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 18:ehad519. doi: 10.1093/eurheartj/ehad519. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37592857/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230821140833&v=2.17.9.post6+86293ac">37592857</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad519>10.1093/eurheartj/ehad519</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37592857</guid>
<pubDate>Fri, 18 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Goaris W A Aarts</dc:creator>
<dc:creator>Cyril Camaro</dc:creator>
<dc:creator>Niels van Royen</dc:creator>
<dc:date>2023-08-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Ready for rapid rule-out of acute myocardial infarction</dc:title>
<dc:identifier>pmid:37592857</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad519</dc:identifier>
</item>
<item>
<title>End-stage heart failure in congenitally corrected transposition of the great arteries: a multicentre study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37592821/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230821140833&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Patients with ccTGA have variable deterioration to end-stage heart failure or death over time, commonly between their fifth and sixth decades. Predictors include arrhythmic and CHF events and severe RV dysfunction but not anatomy or need for tricuspid valve surgery.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 18:ehad511. doi: 10.1093/eurheartj/ehad511. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: For patients with congenitally corrected transposition of the great arteries (ccTGA), factors associated with progression to end-stage congestive heart failure (CHF) remain largely unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This multicentre, retrospective cohort study included adults with ccTGA seen at a congenital heart disease centre. Clinical data from initial and most recent visits were obtained. The composite primary outcome was mechanical circulatory support, heart transplantation, or death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: From 558 patients (48% female, age at first visit 36 ± 14.2 years, median follow-up 8.7 years), the event rate of the primary outcome was 15.4 per 1000 person-years (11 mechanical circulatory support implantations, 12 transplantations, and 52 deaths). Patients experiencing the primary outcome were older and more likely to have a history of atrial arrhythmia. The primary outcome was highest in those with both moderate/severe right ventricular (RV) dysfunction and tricuspid regurgitation (n = 110, 31 events) and uncommon in those with mild/less RV dysfunction and tricuspid regurgitation (n = 181, 13 events, P &lt; .001). Outcomes were not different based on anatomic complexity and history of tricuspid valve surgery or of subpulmonic obstruction. New CHF admission or ventricular arrhythmia was associated with the primary outcome. Individuals who underwent childhood surgery had more adverse outcomes than age- and sex-matched controls. Multivariable Cox regression analysis identified older age, prior CHF admission, and severe RV dysfunction as independent predictors for the primary outcome.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients with ccTGA have variable deterioration to end-stage heart failure or death over time, commonly between their fifth and sixth decades. Predictors include arrhythmic and CHF events and severe RV dysfunction but not anatomy or need for tricuspid valve surgery.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37592821/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230821140833&v=2.17.9.post6+86293ac">37592821</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad511>10.1093/eurheartj/ehad511</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37592821</guid>
<pubDate>Fri, 18 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Alexandra C van Dissel</dc:creator>
<dc:creator>Alexander R Opotowsky</dc:creator>
<dc:creator>Luke J Burchill</dc:creator>
<dc:creator>Jamil Aboulhosn</dc:creator>
<dc:creator>Jasmine Grewal</dc:creator>
<dc:creator>Adam M Lubert</dc:creator>
<dc:creator>Petra Antonova</dc:creator>
<dc:creator>Sangeeta Shah</dc:creator>
<dc:creator>Timothy Cotts</dc:creator>
<dc:creator>Anitha S John</dc:creator>
<dc:creator>William Aaron Kay</dc:creator>
<dc:creator>Christopher DeZorzi</dc:creator>
<dc:creator>Anthony Magalski</dc:creator>
<dc:creator>Frank Han</dc:creator>
<dc:creator>David Baker</dc:creator>
<dc:creator>Joseph Kay</dc:creator>
<dc:creator>Elizabeth Yeung</dc:creator>
<dc:creator>Isabelle Vonder Muhll</dc:creator>
<dc:creator>Stephen Pylypchuk</dc:creator>
<dc:creator>Marissa C Kuo</dc:creator>
<dc:creator>Jeremy Nicolarsen</dc:creator>
<dc:creator>Berardo Sarubbi</dc:creator>
<dc:creator>Flavia Fusco</dc:creator>
<dc:creator>Susan M Jameson</dc:creator>
<dc:creator>Jonathan Cramer</dc:creator>
<dc:creator>Tripti Gupta</dc:creator>
<dc:creator>Pastora Gallego</dc:creator>
<dc:creator>Clare O'Donnell</dc:creator>
<dc:creator>Jane Hannah</dc:creator>
<dc:creator>Mikael Dellborg</dc:creator>
<dc:creator>Robert M Kauling</dc:creator>
<dc:creator>Salil Ginde</dc:creator>
<dc:creator>Eric V Krieger</dc:creator>
<dc:creator>Fred Rodriguez</dc:creator>
<dc:creator>Payam Dehghani</dc:creator>
<dc:creator>Shelby Kutty</dc:creator>
<dc:creator>Joshua Wong</dc:creator>
<dc:creator>William M Wilson</dc:creator>
<dc:creator>Carla P Rodriguez-Monserrate</dc:creator>
<dc:creator>Jolien Roos-Hesselink</dc:creator>
<dc:creator>David S Celermajer</dc:creator>
<dc:creator>Paul Khairy</dc:creator>
<dc:creator>Craig S Broberg</dc:creator>
<dc:date>2023-08-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>End-stage heart failure in congenitally corrected transposition of the great arteries: a multicentre study</dc:title>
<dc:identifier>pmid:37592821</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad511</dc:identifier>
</item>
<item>
<title>Predictors of embolism and death in left-sided infective endocarditis: the European Society of Cardiology EURObservational Research Programme European Infective Endocarditis registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37592753/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230821140833&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Prognosis after LSIE is determined by multiple factors, including vegetation size.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 18:ehad507. doi: 10.1093/eurheartj/ehad507. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Even though vegetation size in infective endocarditis (IE) has been associated with embolic events (EEs) and mortality risk, it is unclear whether vegetation size associated with these potential outcomes is different in left-sided IE (LSIE). This study aimed to seek assessing the vegetation cut-off size as predictor of EE or 30-day mortality for LSIE and to determine risk predictors of these outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The European Society of Cardiology EURObservational Research Programme European Infective Endocarditis is a prospective, multicentre registry including patients with definite or possible IE throughout 2016-18. Cox multivariable logistic regression analysis was performed to assess variables associated with EE or 30-day mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: There were 2171 patients with LSIE (women 31.5%). Among these affected patients, 459 (21.1%) had a new EE or died in 30 days. The cut-off value of vegetation size for predicting EEs or 30-day mortality was >;10 mm [hazard ratio (HR) 1.38, 95% confidence interval (CI) 1.13-1.69, P = .0015]. Other adjusted predictors of risk of EE or death were as follows: EE on admission (HR 1.89, 95% CI 1.54-2.33, P &lt; .0001), history of heart failure (HR 1.53, 95% CI 1.21-1.93, P = .0004), creatinine >;2 mg/dL (HR 1.59, 95% CI 1.25-2.03, P = .0002), Staphylococcus aureus (HR 1.36, 95% CI 1.08-1.70, P = .008), congestive heart failure (HR 1.40, 95% CI 1.12-1.75, P = .003), presence of haemorrhagic stroke (HR 4.57, 95% CI 3.08-6.79, P &lt; .0001), alcohol abuse (HR 1.45, 95% CI 1.04-2.03, P = .03), presence of cardiogenic shock (HR 2.07, 95% CI 1.29-3.34, P = .003), and not performing left surgery (HR 1.30 95% CI 1.05-1.61, P = .016) (C-statistic = .68).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Prognosis after LSIE is determined by multiple factors, including vegetation size.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37592753/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230821140833&v=2.17.9.post6+86293ac">37592753</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad507>10.1093/eurheartj/ehad507</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37592753</guid>
<pubDate>Fri, 18 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Antonia Sambola</dc:creator>
<dc:creator>Jordi Lozano-Torres</dc:creator>
<dc:creator>Eric Boersma</dc:creator>
<dc:creator>Carmen Olmos</dc:creator>
<dc:creator>Julien Ternacle</dc:creator>
<dc:creator>Francisco Calvo</dc:creator>
<dc:creator>Christophe Tribouilloy</dc:creator>
<dc:creator>Vlatka Reskovic-Luksic</dc:creator>
<dc:creator>Jadranka Separovic-Hanzevacki</dc:creator>
<dc:creator>Seung-Woo Park</dc:creator>
<dc:creator>Sebastiaan Bekkers</dc:creator>
<dc:creator>Kwan-Leung Chan</dc:creator>
<dc:creator>Abdallah Almaghraby</dc:creator>
<dc:creator>Bernard Iung</dc:creator>
<dc:creator>Patrizio Lancellotti</dc:creator>
<dc:creator>Gilbert Habib</dc:creator>
<dc:creator>ESC EORP EURO-ENDO Registry Investigator Group</dc:creator>
<dc:date>2023-08-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Predictors of embolism and death in left-sided infective endocarditis: the European Society of Cardiology EURObservational Research Programme European Infective Endocarditis registry</dc:title>
<dc:identifier>pmid:37592753</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad507</dc:identifier>
</item>
<item>
<title>Congenitally corrected transposition of the great arteries: have we shifted the disease 'trajectory?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37592741/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230821140833&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 18:ehad482. doi: 10.1093/eurheartj/ehad482. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37592741/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230821140833&v=2.17.9.post6+86293ac">37592741</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad482>10.1093/eurheartj/ehad482</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37592741</guid>
<pubDate>Fri, 18 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Magalie Ladouceur</dc:creator>
<dc:date>2023-08-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Congenitally corrected transposition of the great arteries: have we shifted the disease 'trajectory?</dc:title>
<dc:identifier>pmid:37592741</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad482</dc:identifier>
</item>
<item>
<title>The projection-specific signals that establish functionally segregated dopaminergic synapses</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37591240/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230821140833&amp;v=2.17.9.post6+86293ac
      <description>Dopaminergic projections regulate various brain functions and are implicated in many neuropsychiatric disorders. There are two anatomically and functionally distinct dopaminergic projections connecting the midbrain to striatum: nigrostriatal, which controls movement, and mesolimbic, which regulates motivation. However, how these discrete dopaminergic synaptic connections are established is unknown. Through an unbiased search, we identify that two groups of antagonistic TGF-β family members, bone...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 9:S0092-8674(23)00801-2. doi: 10.1016/j.cell.2023.07.023. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Dopaminergic projections regulate various brain functions and are implicated in many neuropsychiatric disorders. There are two anatomically and functionally distinct dopaminergic projections connecting the midbrain to striatum: nigrostriatal, which controls movement, and mesolimbic, which regulates motivation. However, how these discrete dopaminergic synaptic connections are established is unknown. Through an unbiased search, we identify that two groups of antagonistic TGF-β family members, bone morphogenetic protein (BMP)6/BMP2 and transforming growth factor (TGF)-β2, regulate dopaminergic synapse development of nigrostriatal and mesolimbic neurons, respectively. Projection-preferential expression of their receptors contributes to specific synapse development. Downstream, Smad1 and Smad2 are specifically activated and required for dopaminergic synapse development and function in nigrostriatal vs. mesolimbic projections. Remarkably, Smad1 mutant mice show motor defects, whereas Smad2 mutant mice show lack of motivation. These results uncover the molecular logic underlying the proper establishment of functionally segregated dopaminergic synapses and may provide strategies to treat relevant, projection-specific disease symptoms by targeting specific BMPs/TGF-β and/or Smads.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37591240/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230821140833&v=2.17.9.post6+86293ac">37591240</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.07.023>10.1016/j.cell.2023.07.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37591240</guid>
<pubDate>Thu, 17 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Akiko Terauchi</dc:creator>
<dc:creator>Patricia Yee</dc:creator>
<dc:creator>Erin M Johnson-Venkatesh</dc:creator>
<dc:creator>Mariel P Seiglie</dc:creator>
<dc:creator>Lisa Kim</dc:creator>
<dc:creator>Julia C Pitino</dc:creator>
<dc:creator>Eli Kritzer</dc:creator>
<dc:creator>Qiyu Zhang</dc:creator>
<dc:creator>Jie Zhou</dc:creator>
<dc:creator>Yulong Li</dc:creator>
<dc:creator>David D Ginty</dc:creator>
<dc:creator>Wei-Chung A Lee</dc:creator>
<dc:creator>Hisashi Umemori</dc:creator>
<dc:date>2023-08-17</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The projection-specific signals that establish functionally segregated dopaminergic synapses</dc:title>
<dc:identifier>pmid:37591240</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.07.023</dc:identifier>
</item>





























</channel>
</rss>